Treatment with Armolipid Plus led to a significant reduction of total cholesterol ( -12.8 % ) and low-density lipoprotein-cholesterol ( -21.1 % ) , similar to pravastatin ( -16 % and -22.6 % , respectively ) , and an increase of high-density lipoprotein-cholesterol ( 4.8 % ) .